CYMBALTA (duloxetine hydrochloride) is indicated for the symptomatic relief of major depressive disorder (MDD). The efficacy of CYMBALTA in
CYMBALTA (duloxetine hydrochloride) is indicated for the symptomatic relief of major depressive disorder (MDD). The efficacy of CYMBALTA in
התוויה המאושרת לתכשיר: Cymbalta is indicated for the treatment of major depressive episodes. − Cymbalta is indicated for the management of neuropathic pain
CYMBALTA (duloxetine hydrochloride) is indicated for the symptomatic relief of major depressive disorder (MDD). The efficacy of CYMBALTA in
CYMBALTA is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN). Fibromyalgia. CYMBALTA is
CYMBALTA (duloxetine hydrochloride) is indicated for the symptomatic relief of major depressive disorder (MDD). The efficacy of CYMBALTA in
Cymbalta is indicated for the management of fibromyalgia (FM) [see Clinical Studies (14.4)]. 1.5. Chronic Musculoskeletal Pain. Cymbalta is indicated for the
CYMBALTA (duloxetine hydrochloride) is indicated for the symptomatic relief of major depressive disorder (MDD). The efficacy of CYMBALTA in
Cymbalta (duloxetine) is a prescription medication indicated in the treatment of both MDD and GAD. Cymbalta belongs to a group of
Comments